Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

ReproNovo raises $65M for trials of leflutrozole and nolasiban in reproductive health. CEO Jean Marie Duvall plans Phase 2 ...

Duncan Reece shares why his dementia care startup Veronica Health closed before seeing patients, citing fundraising challenges and investor skepticism of value-based care.

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US ...

Biotech execs express concerns over FDA changes, NIH cuts, and Trump's tariffs. Industry confidence low amid poor funding ...

Calibrate names Rob Rebak as new CEO, replacing Rob MacNaughton, amid executive changes. CFO and Chief Clinical Officer also ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the ...

A longevity startup called Retro Biosciences is working on personalized blood disorder therapies thanks to a partnership with ...

Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the ...

Apnimed's oral drug met the efficacy bar in the first of two Phase 3 studies in obstructive sleep apnea, the biotech said ...